📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
131 announcements match the current filters (relevance ≥ 5).
CPPLUS Q3 Profit Surges 139% YoY to ₹960M; Announces JV and New Greenfield Project
Aditya Infotech (CPPLUS) reported a stellar Q3 FY26 with consolidated revenue rising 37% YoY to ₹11,391 million and net profit jumping 139% YoY to ₹959.8 million. The company is aggressively expanding through a 50:50 Joint Venture with Orient Cables for manufacturing LAN and CCTV cables. Additionally, its subsidiary AIL Dixon Technologies is setting up a greenfield facility in Kadapa for backward integration into housing components and augmenting existing plant capacity. These strategic moves are designed to optimize costs and strengthen the supply chain.
Key Highlights
Q3 FY26 Net Profit surged 139% YoY to ₹959.8 million from ₹401.9 million in the previous year.
Revenue from operations grew to ₹11,391.1 million in Q3 FY26, a 37% increase compared to Q3 FY25.
Entered a 50:50 Joint Venture with Orient Cables (India) Limited for manufacturing electric and CCTV cables.
Establishing a greenfield project in Kadapa, Andhra Pradesh, for in-house manufacturing of plastic and metal housing components.
Proposed capacity augmentation at the existing Kadapa manufacturing plant through subsidiary AIL Dixon Technologies.
👀 What to Watch
The strong earnings growth combined with aggressive backward integration and capacity expansion signals robust future margins and market share gains. Investors should remain positive on the stock as these capital expenditures begin to contribute to the bottom line.
Aditya Infotech (CPPLUS) Q3 Profit Jumps 37% QoQ; Announces JV and New Greenfield Project
Aditya Infotech reported a strong Q3 FY26 performance with consolidated revenue reaching ₹11,391.10 million and net profit growing to ₹959.80 million, up from ₹699.75 million in the previous quarter. The company announced a 50:50 Joint Venture with Orient Cables to manufacture LAN and CCTV cables, strengthening its supply chain. Furthermore, it is initiating a greenfield project in Kadapa for backward integration into plastic and metal housing components. The board also approved capacity expansion at its existing Kadapa plant and granted Dixon Technologies a board nomination right.
Key Highlights
Consolidated revenue for Q3 FY26 rose to ₹11,391.10 million versus ₹9,196.36 million in Q2.
Net profit for the quarter stood at ₹959.80 million, representing a 37% sequential growth.
Signed a 50:50 JV MoU with Orient Cables (India) Limited for manufacturing electric and CCTV cables.
Approved a greenfield project in Kadapa for in-house manufacturing of plastic and metal housing components.
Amended Articles of Association to allow Dixon Technologies (India) Limited to nominate one Director to the Board.
👀 What to Watch
Investors should take note of the robust sequential earnings growth and the strategic shift toward backward integration which likely aims at margin expansion. The partnership with Dixon Technologies and the new JV provide strong visibility for future scaling.
Aditya Infotech (CPPLUS) Q3 PAT at ₹960M; Announces 50:50 JV and New Greenfield Project
Aditya Infotech Limited (CPPLUS) reported a strong Q3 FY26 with consolidated revenue of ₹11,391.10 million and a net profit of ₹959.80 million. The company has entered into a 50:50 Joint Venture with Orient Cables (India) Limited to manufacture LAN and CCTV cables, enhancing its supply chain. Furthermore, its subsidiary AIL Dixon Technologies is initiating a greenfield project in Kadapa for backward integration into housing components and expanding existing plant capacity. The board also approved a director nomination right for Dixon Technologies (India) Limited, strengthening the strategic partnership.
Key Highlights
Consolidated Revenue for Q3 FY26 reached ₹11,391.10 million, showing significant growth over previous periods.
Net Profit for the quarter ended December 31, 2025, stood at ₹959.80 million with an EPS of ₹8.18.
Signed a 50:50 Joint Venture MoU with Orient Cables for manufacturing electric, LAN, and CCTV cables.
Announced a new greenfield project in Kadapa, Andhra Pradesh, for backward integration of plastic and metal housing components.
Approved capacity augmentation at the existing Kadapa manufacturing plant to optimize operational efficiency.
👀 What to Watch
Investors should note the aggressive backward integration and capacity expansion which are likely to improve margins and reduce supply chain risks. The strategic alignment with Dixon Technologies and the new JV for cable manufacturing provide a strong foundation for long-term growth in the security surveillance market.
Aditya Infotech (CPPLUS) Q3 PAT Surges 139% to ₹96 Cr; Upgrades FY26 Guidance
Aditya Infotech Limited (CPPLUS) reported robust Q3 FY26 results with revenue growing 37.3% YoY to ₹1,139.1 crore and adjusted PAT jumping 138.8% to ₹96 crore. The company achieved significant margin expansion, with EBITDA margins rising 391 bps to 12.7% due to higher localization and favorable operating leverage. Management has upgraded its FY26 guidance, now targeting EBITDA margins of 11-12% and PAT margins of 7-7.5%. Strategic developments include a collaboration with Qualcomm for AI-enabled security and the launch of the 'Nexivue' brand for mass markets.
Key Highlights
Q3 FY26 Revenue increased 37.3% YoY to ₹1,139.1 crore, while EBITDA surged 98.7% to ₹144.6 crore.
9M FY26 Adjusted PAT grew by 138.6% YoY to ₹198.9 crore, reflecting strong operational execution.
Market share in the video surveillance segment reached ~38.9% in Q2 FY26, a gain of 7.5% QoQ.
Manufacturing capacity is being scaled from 1.8 million to 2.1 million units per month by Q4 FY26.
Upgraded FY26 guidance projects EBITDA margins of 11-12% and PAT margins of 7-7.5%.
👀 What to Watch
Investors should note the significant guidance upgrade and market share gains as evidence of the company's strengthening competitive position. The focus on backward integration and AI-led solutions through the Qualcomm partnership suggests sustainable long-term growth.
Aditya Infotech (CPPLUS) Q3 PAT Jumps 37% QoQ to ₹96 Cr; Announces JV and Expansion
Aditya Infotech Limited (CPPLUS) reported a strong performance for Q3 FY26, with consolidated revenue reaching ₹11,391.10 million, up from ₹9,196.36 million in the previous quarter. Net profit for the quarter rose significantly to ₹959.80 million, compared to ₹699.75 million in Q2 FY26. The company is aggressively pursuing backward integration through a new 50:50 Joint Venture with Orient Cables and a greenfield project in Kadapa for housing components. Furthermore, the board has approved a director nomination right for Dixon Technologies, strengthening their strategic partnership.
Key Highlights
Consolidated Revenue for Q3 FY26 grew 23.8% sequentially to ₹11,391.10 million.
Net Profit (PAT) surged 37.1% QoQ to ₹959.80 million with an EPS of ₹8.18.
Entered a 50:50 Joint Venture with Orient Cables for manufacturing LAN and CCTV cables.
Subsidiary AIL Dixon Technologies to set up a greenfield project in Kadapa, AP, for plastic and metal housing components.
Proposed AoA amendment to allow Dixon Technologies (India) Limited to nominate one Director to the Board.
👀 What to Watch
The strong earnings growth combined with strategic backward integration and capacity expansion makes this a positive outlook. Investors should watch for the formalization of the Orient Cables JV and the impact of the new Kadapa facility on margins.
Piramal Pharma Faces Rs 1 Crore Environmental Penalty for Dahej Plant
Piramal Pharma has been hit with an interim environmental damage compensation (EDC) of Rs. 1 crore by the Gujarat Pollution Control Board (GPCB). This penalty follows a previous closure direction issued on February 4, 2026, for the company's manufacturing facility located in Dahej, Gujarat. The company is currently engaging with regulatory authorities and the courts to seek an expedited resolution to the matter. Management states that beyond the EDC and a previously disclosed bank guarantee, there is no material impact on financial or operational activities at this time.
Key Highlights
GPCB imposed an interim environmental damage compensation of Rs. 1 crore on the Dahej site.
The penalty is linked to a closure direction issued under Section 33-A of the Water Act on February 4, 2026.
The affected facility is located at Plot No. D-2/11/A/1, GIDC Dahej, Bharuch, Gujarat.
Company is pursuing legal and regulatory channels to resolve the compliance issues and resume full operations.
👀 What to Watch
Investors should monitor the timeline for the lifting of the closure direction at the Dahej site, as prolonged downtime could affect production. While the Rs. 1 crore penalty is financially small, the regulatory oversight remains a point of concern for operational stability.
GPPL Q3 FY26: Net Profit Rises 8% to ₹1,013 Mn; EBITDA Margin Expands to 55%
Gujarat Pipavav Port (GPPL) reported a steady Q3 FY26 performance with revenue growing 11% YoY to ₹2,923 million. EBITDA increased by 16% YoY to ₹1,604 million, with margins expanding to 55% from 53% in the previous year. While container volumes saw a marginal decline to 175k TEUs, the RoRo and Bulk segments showed robust growth of 39% and 25% respectively. Net profit for the quarter stood at ₹1,013 million, marking an 8% growth over the same period last year.
Key Highlights
Revenue from operations grew 11% YoY to ₹2,923 million in Q3 FY26.
EBITDA rose 16% YoY to ₹1,604 million with a healthy margin expansion to 55%.
RoRo volumes surged by 39% YoY to 62,163 units driven by higher OEM volumes.
Bulk cargo volumes increased by 25% YoY to 914,000 MTs, supported by fertilizer and limestone.
Net profit increased by 8% YoY to ₹1,013 million despite a slight dip in container volumes.
👀 What to Watch
Investors should take note of the strong margin expansion and diversification into Bulk and RoRo segments which are offsetting container volume stagnation. The company remains a fundamentally strong play in the port sector with efficient operations.
GPPL Q3 FY26 Net Profit Rises 7.8% YoY to ₹101.3 Crore; Revenue Up 11.2%
Gujarat Pipavav Port Limited (GPPL) reported a steady Q3 FY26 with revenue from operations reaching ₹292.25 crore, up from ₹262.89 crore in the previous year. Net profit grew to ₹101.31 crore despite an exceptional loss of ₹4.81 crore related to the implementation of new Labour Codes. The company's nine-month performance remains strong with a 24% increase in net profit compared to the same period last year. Investors should monitor the ongoing ₹55.6 crore dispute with the Gujarat Maritime Board which remains in the resolution phase.
Key Highlights
Revenue from operations increased 11.2% YoY to ₹2,922.51 million for the quarter ended Dec 31, 2025.
Net profit for the quarter stood at ₹1,013.08 million, up from ₹939.86 million in Q3 FY25.
Nine-month (9M FY26) net profit surged to ₹3,603.47 million compared to ₹2,901.24 million in 9M FY25.
Recognized an exceptional loss of ₹48.11 million due to incremental gratuity costs from new Labour Code definitions.
Earnings Per Share (EPS) for the quarter improved to ₹2.10 from ₹1.94 YoY.
👀 What to Watch
Maintain a positive outlook as the company shows consistent growth in core port operations and strong 9M profitability. Investors should hold for steady dividends but keep an eye on the final resolution of the GMB legal dispute.
Rajshree Polypack Q3 FY26 PAT Rises 25.38% YoY to ₹2.13 Cr; Export Revenue Surges 41%
Rajshree Polypack reported a resilient Q3 FY26 with PAT growing 25.38% YoY to ₹2.13 Cr, despite a marginal 1.49% dip in revenue to ₹71.62 Cr. The company achieved significant margin expansion, with EBITDA margins rising to 14.38% from 12.45% in the previous year. High-growth segments led the performance, as export revenue jumped 40.83% YoY and injection moulding revenue increased 37.39% YoY. Additionally, the Olive Ecopack joint venture showed a strong turnaround, reaching a positive EBITDA margin of 7.35%.
Key Highlights
PAT increased by 25.38% YoY to ₹2.13 Cr, while EBITDA grew 13.82% to ₹10.30 Cr.
Export revenue grew by 40.83% YoY in Q3 and 63.16% YoY for the nine-month period.
Injection moulding capacity expanded to 4,800 MTPA, with segment revenue rising 37.39% YoY.
Olive Ecopack JV revenue grew 30.2% QoQ to ₹15.69 Cr with a sharp turnaround in EBITDA margins to 7.35%.
New 1.9 MW wind-solar captive power arrangement expected to save ₹1.75 Cr annually.
👀 What to Watch
Investors should focus on the company's successful shift toward high-margin exports and injection moulding segments which are offsetting flat domestic volumes. The operational turnaround of the Olive Ecopack JV is a key positive catalyst for consolidated earnings growth.
Rajshree Polypack Board Approves Q3 and 9M FY26 Financial Results
Rajshree Polypack Limited's Board of Directors met on February 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The meeting was conducted in compliance with SEBI Listing Regulations and included a Limited Review Report from statutory auditors M/s. JASS & CO LLP. While the cover letter confirms the approval of results, specific revenue and profit figures were submitted as separate attachments. This announcement marks the official reporting of the company's performance for the third quarter of the fiscal year.
Key Highlights
Board approved unaudited standalone and consolidated financial results for the period ended December 31, 2025.
The statutory auditor M/s. JASS & CO LLP issued a Limited Review Report for the nine-month period.
The board meeting was held on February 06, 2026, lasting approximately 30 minutes from 12:35 P.M. to 1:05 P.M.
Submission made in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should review the detailed financial tables in the full filing to analyze revenue growth and margin trends for the quarter. Compare the Q3 performance against previous quarters to assess the company's operational consistency in the packaging sector.
Rajshree Polypack Approves Q3 and Nine Months Ended Dec 2025 Financial Results
Rajshree Polypack Limited's Board of Directors met on February 06, 2026, to approve the un-audited financial results for the quarter and nine months ending December 31, 2025. The approval encompasses both standalone and consolidated financial statements, providing a full view of the company's performance. The results were accompanied by a Limited Review Report from the statutory auditors, M/s. JASS & CO LLP. This procedural announcement confirms the formal adoption of the third-quarter performance metrics.
Key Highlights
Board approved un-audited standalone and consolidated financial results for the quarter ended December 31, 2025
Financial results for the nine-month period ended December 31, 2025, were also reviewed and approved
Statutory auditors M/s. JASS & CO LLP issued a Limited Review Report on the financial statements
The board meeting was held on February 06, 2026, lasting 30 minutes from 12:35 P.M. to 1:05 P.M.
👀 What to Watch
Investors should examine the detailed financial tables in the full report to evaluate revenue growth and margin trends for the quarter. Compare the Q3 performance against the previous year's corresponding quarter to assess the company's growth trajectory.
Piramal Pharma Partners with Blue-Zone to Recycle Waste Anesthetic Gases in Europe and Canada
Piramal Critical Care (PCC), a subsidiary of Piramal Pharma, has entered a strategic collaboration with Blue-Zone Technologies to capture and recycle waste anesthetic gases. The partnership will initially deploy Blue-Zone’s Phoenix Deltasorb technology in France and Germany, pending regulatory approval. PCC will process the captured gas to produce Sevoflurane USP in Canada, creating a sustainable full-lifecycle model for essential anesthetics. This initiative aligns with global ESG trends and leverages Piramal's existing distribution network across 100+ countries.
Key Highlights
Strategic collaboration to capture, collect, and recycle waste anesthetic gases using Blue-Zone technology.
Initial rollout targeted for France and Germany following European regulatory approval of the Phoenix Deltasorb system.
PCC will manufacture Sevoflurane USP from recycled gases at its Canadian facilities.
Leverages Piramal Pharma's global infrastructure of 17 facilities and distribution in over 100 countries.
👀 What to Watch
Investors should monitor the progress of regulatory approvals in Europe and the subsequent scaling of this technology. This move strengthens the company's ESG credentials and could provide a competitive edge in hospital procurement processes focused on sustainability.
Piramal Pharma Receives GPCB Closure Notice for Dahej Plant; Rs 15 Lakh Bank Guarantee Mandated
Piramal Pharma Limited has received a closure notice from the Gujarat Pollution Control Board (GPCB) for its manufacturing facility in Dahej, Gujarat. The notice, received on February 3, 2026, mandates the shutdown of industrial activities within 48 hours due to alleged violations of the Water Pollution Act. The company is also required to furnish a bank guarantee of Rs. 15,00,000. Piramal Pharma is contesting the order and is filing an urgent Writ Petition in the Gujarat High Court to seek an immediate stay on the closure.
Key Highlights
GPCB directed closure of the Dahej site within 48 hours of notice receipt on February 3, 2026
Alleged violations involve Section 33-A of the Water (Prevention and Control of Pollution) Act, 1974
Company must submit a bank guarantee of Rs. 15,00,000 with a one-year validity period
Piramal Pharma is seeking expedited intervention from the Gujarat High Court to reverse the order
Operational and financial impact of the potential shutdown is currently being evaluated
👀 What to Watch
Investors should monitor the Gujarat High Court's response to the Writ Petition as a prolonged shutdown could impact production schedules. The immediate focus should be on whether the company secures an interim stay to continue operations.
Aditya Infotech (CPPLUS) Incorporates Taiwan R&D Subsidiary with NT$ 5 Million Investment
Aditya Infotech Limited has successfully incorporated its wholly-owned subsidiary, Aditya Infotech Taiwan Co. Ltd., on February 02, 2026. The new entity is located in Taiwan and will focus primarily on Research & Development (R&D) for security and surveillance equipment. The company has committed an initial cash investment of NT$ 5 million for a 100% stake. This move follows the strategic board approval granted in September 2025 to bolster the company's technological capabilities.
Key Highlights
Incorporation of 100% wholly-owned subsidiary named Aditya Infotech Taiwan Co. Ltd. in Taiwan
Initial capital investment of NT$ 5 million (New Taiwan Dollars) in cash
Primary business focus on R&D activities for security and surveillance equipment
Strategic expansion into a global technology hub to enhance product innovation
👀 What to Watch
Investors should monitor how this R&D expansion into Taiwan improves the company's product pipeline and technological edge in the competitive surveillance market. This is a positive long-term move for intellectual property development.
Piramal Pharma Q3 FY26: Revenue Down 3%, EBITDA Drops 32% Amid CDMO Headwinds
Piramal Pharma reported a weak Q3 FY26 with consolidated revenue declining 3% YoY to ₹2,140 crore and EBITDA falling 32% to ₹239 crore. The performance was primarily dragged down by the CDMO segment, which saw a 9% revenue dip due to inventory destocking and slow US biopharma funding. Despite these challenges, the Consumer Healthcare segment grew 20% YoY, and the company reported a recovery in order inflows starting October 2025. The company also announced the acquisition of the Kenalog brand for an upfront $35 million to bolster its Hospital Generics portfolio.
Key Highlights
Consolidated EBITDA margins contracted significantly to 11% in Q3FY26 from 16% in Q3FY25.
CDMO revenue fell 9% YoY to ₹1,166 crore, impacted by inventory destocking and regulatory delays at the Digwal facility.
Consumer Healthcare (PCH) segment grew 20% YoY, with power brands growing 30% and e-commerce sales up 50%.
Acquired Kenalog injectable from Bristol-Myers Squibb for $35M upfront plus up to $65M in contingent payments.
Reported a net loss of ₹136 crore for Q3FY26, compared to a profit of ₹4 crore in the previous year's quarter.
👀 What to Watch
Investors should exercise caution due to the sharp margin contraction and CDMO segment weakness, while monitoring if the 'early signs of recovery' in order inflows translate into a stronger Q4. The acquisition of Kenalog and the $90M US expansion are long-term positives, but short-term profitability remains under pressure.
Piramal Pharma Q3FY26: Revenue Down 3%, EBITDA Drops 32% Amid CDMO Headwinds
Piramal Pharma reported a weak Q3FY26 with consolidated revenue declining 3% YoY to ₹2,140 crore, primarily due to a 9% drop in the CDMO segment caused by inventory destocking and slower order inflows. EBITDA margins contracted significantly to 11% from 16% YoY, resulting in a net loss of ₹136 crore for the quarter. Despite the poor quarterly performance, the company noted a recovery in RFPs and order inflows since October 2025 and announced the acquisition of Kenalog for up to $100 million. Management expects the historically strong Q4 to drive a recovery in the final quarter of the fiscal year.
Key Highlights
Consolidated Revenue declined 3% YoY to ₹2,140 Cr, while EBITDA fell 32% to ₹239 Cr.
Reported a Net Loss of ₹136 Cr in Q3FY26 compared to a profit of ₹4 Cr in the previous year.
CDMO revenue dropped 9% YoY to ₹1,166 Cr, while Consumer Healthcare (PCH) grew 20% to ₹334 Cr.
Acquired Kenalog from Bristol-Myers Squibb for an upfront $35M and up to $65M in contingent payments.
E-commerce sales in the Consumer Healthcare segment grew 50% YoY, now contributing 26% of PCH sales.
👀 What to Watch
Investors should exercise caution due to the significant margin contraction and net loss, but monitor the promised recovery in Q4 and the impact of the Kenalog acquisition. The pick-up in CDMO order inflows since October 2025 is a key metric to watch for a potential turnaround in FY27.
Piramal Pharma Q3 Results: Consolidated Net Loss Widens to ₹136 Cr; Revenue Dips 3% YoY
Piramal Pharma reported a weak consolidated performance for Q3 FY26, with revenue from operations declining 2.9% YoY to ₹2,139.87 crore. The company swung to a consolidated net loss of ₹136.19 crore from a marginal profit of ₹3.68 crore in the previous year's corresponding quarter. Results were further weighed down by an exceptional charge of ₹41.11 crore on a consolidated basis due to the implementation of new Labour Codes. Despite the consolidated loss, standalone net profit showed a slight improvement, rising to ₹128.91 crore.
Key Highlights
Consolidated revenue from operations decreased by 2.9% YoY to ₹2,139.87 crore.
Reported a consolidated net loss of ₹136.19 crore compared to a profit of ₹3.68 crore in Q3 FY25.
Exceptional item of ₹41.11 crore recognized at the consolidated level for New Labour Code compliance.
Finance costs reduced to ₹89.24 crore from ₹103.31 crore in the year-ago period.
9-month consolidated net loss widened to ₹317.11 crore versus a loss of ₹62.37 crore in the previous year.
👀 What to Watch
The widening consolidated loss and stagnant revenue growth are concerning for short-term sentiment. Investors should exercise caution and wait for management commentary regarding the path to profitability and the impact of rising employee costs.
Piramal Pharma Announces Senior Management Changes and New Interim Company Secretary
Piramal Pharma has formally designated four senior officials as Senior Management Personnel (SMP) to lead critical functions including Quality, M&A, Legal, and HR. Ms. Tanya Sanish has resigned from her role as Company Secretary and Compliance Officer effective February 20, 2026, to pursue external opportunities. Ms. Pratibha Mishra, who has over 10 years of experience and has been with the firm since 2022, will take over as the Interim Company Secretary from February 21, 2026. The new SMPs bring significant expertise, with the heads of Quality and M&A each possessing over 25 years of industry experience.
Key Highlights
Four officials designated as Senior Management Personnel (SMP) including Chief Quality Officer and President-M&A
Ms. Rashida Najmi (CQO) and Mr. Jatin Lal (M&A) bring over 26 and 25 years of industry experience respectively
Company Secretary Tanya Sanish resigns effective February 20, 2026; Pratibha Mishra appointed as Interim CS
The new SMP team covers critical operational areas: Quality, M&A, Legal, and Human Resources
👀 What to Watch
These management changes represent a formalization of the leadership structure and a routine transition in the secretarial department. Investors should view this as neutral and continue to monitor the company's execution of its growth and M&A strategies.
Piramal Pharma to Acquire Kenalog Brand from BMS for Up to $100 Million
Piramal Pharma's subsidiary, Piramal Critical Care B.V., has signed a definitive agreement to acquire the Kenalog brand and associated trademarks from Bristol-Myers Squibb (BMS). The deal involves an upfront payment of $35 million and milestone-based contingent payments of up to $65 million. Kenalog is a branded injectable corticosteroid used for inflammatory conditions and is currently marketed across 15 countries. This acquisition is designed to strengthen Piramal's Complex Hospital Generics (CHG) portfolio and leverage its global distribution network.
Key Highlights
Total potential deal value of $100 million, including $35 million upfront and $65 million in milestones.
Acquisition includes multiple trademarks such as Kenalog, Kenacort, Trigon, and Adcortyl across 15 countries.
Target product is a synthetic corticosteroid indicated for rheumatoid arthritis and acute gouty arthritis.
Strategic fit to leverage Piramal's network of 6,000+ hospitals in over 100 countries.
Expansion focus specifically targets growth in the US, Europe, and Asia-Pacific markets.
👀 What to Watch
Investors should view this as a positive move to enhance the high-margin branded product portfolio. Monitor the impact on the Complex Hospital Generics segment's revenue growth and margin profile in the coming fiscal years.
Aditya Infotech (CPPLUS) Secures Rs 36.78 Cr Tax Relief in AY 2019-20 Appeal
Aditya Infotech Limited (CPPLUS) has received a favorable ruling from the Commissioner of Income Tax (Appeals) regarding a tax dispute for Assessment Year 2019-20. The authority waived income additions of approximately Rs 36.78 crore, leaving only a net addition of Rs 3.60 crore from the original Rs 40.38 crore. This ruling drastically reduces the initial tax demand of Rs 18.96 crore (including interest). As the company has already deposited Rs 3.80 crore for a stay of demand, no further immediate cash outflow is anticipated.
Key Highlights
Commissioner of Income Tax (Appeals) waived Rs 36.78 crore of the original Rs 40.38 crore income addition.
Net addition to income reduced to Rs 3.60 crore, significantly lowering the potential tax and interest liability.
The original tax demand of Rs 18.96 crore will be revised downward by the assessing officer following this order.
Company has already deposited Rs 3.80 crore with the tax department, which likely covers the revised liability.
Management intends to contest the remaining Rs 3.60 crore addition before the appropriate higher authority.
👀 What to Watch
Investors should view this as a positive development that mitigates a significant contingent liability. No immediate action is required as the financial impact is now minimal and largely covered by existing deposits.
